What Predicts Beneficial Outcomes in Psychedelic Use? A Quantitative Content Analysis of Psychedelic Health Outcomes

Introduction

Psychedelics encompass serotonergic tryptamines and phenethylamines and, more recently in research contexts, non-serotonergic substances such as ketamine and MDMA. Earlier work has reported potential therapeutic effects across clinical and non-clinical settings, including reductions in substance use problems, improvements in mental health and well-being, and lifestyle changes. Despite growing interest, mechanisms that might underlie enduring benefits remain contested. Two prominent explanatory frameworks are metaphysical belief theory, which emphasises adoption of comforting supernatural or non‑naturalist beliefs after mystical experiences, and predictive self‑binding theory, which emphasises the generation of new psychological insights following perturbations of self‑representations (for example via ego dissolution). Both accounts invoke overlapping subjective states, making empirical discrimination difficult with many designs used to date. Acevedo and colleagues set out to adjudicate between these competing models by analysing unsolicited, naturalistic psychedelic experience reports. The study aimed to test whether altered metaphysical beliefs or psychological insight better predict enduring beneficial outcomes, and whether psychological insight mediates relations between predictors (ego dissolution and therapeutic intent) and outcomes. The analysis used a quantitative content‑coding approach applied to reports drawn from the Erowid.org experience vaults, focusing on non‑clinical, self‑reported effects and longer‑term health and behavioural outcomes.